Compare BHF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | ACAD |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | BHF | ACAD |
|---|---|---|
| Price | $62.61 | $21.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $57.71 | $30.55 |
| AVG Volume (30 Days) | 405.5K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $27.10 | $18.80 |
| Revenue Next Year | $1.09 | $11.70 |
| P/E Ratio | ★ $4.34 | $9.80 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $43.16 | $14.45 |
| 52 Week High | $66.33 | $28.35 |
| Indicator | BHF | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 47.72 |
| Support Level | $59.04 | $21.51 |
| Resistance Level | $62.63 | $22.03 |
| Average True Range (ATR) | 0.54 | 0.61 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 94.13 | 42.51 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.